FDA issues warnings for misbranded COVID-19 antibody tests

By LabPulse.com staff writers

June 18, 2020 -- The U.S. Food and Drug Administration (FDA) has issued warning letters to three companies for marketing "adulterated and misbranded" COVID-19 antibody tests, the first letters of their kind since the onset of the pandemic.

The letters were issued to the following companies:

  • Medakit of Sheung Wan, Hong Kong;
  • Antibodiescheck.com and Yama Group; and
  • Dr. Jason Korkus, DDS and Sonrisa Family Dental, doing business as My COVID19 Club of Chicago.

Listed violations included offering tests directly to U.S. consumers for at-home use without marketing clearance from the FDA, misbranding tests by claiming that they are FDA approved when they are not, and test labeling that shows the FDA logo.

"The FDA reminds the public that, at the present time, there are no diagnostic or antibody COVID-19 test kits that are authorized, cleared or approved to be used completely at home," the agency said in a statement.

The FDA has asked these companies to stop selling these products and block future sales or else face legal action.

"Providing regulatory flexibility during this public health emergency never meant we would allow fraud," said Dr. Jeff Shuren, JD, director of the agency's Center for Devices and Radiological Health. "When tests are marketed inappropriately, with inaccurate or misleading claims -- such as the ability to perform the test completely at home, or that the test is authorized, cleared, or approved when it is not -- they put the health of Americans at risk. Such conduct will not be tolerated by the FDA, and we will continue to monitor tests marketed in the U.S., taking appropriate action as warranted."

FDA finds false results with Chembio coronavirus antibody test, revokes clearance
The U.S. Food and Drug Administration (FDA) has revoked an emergency use authorization for Chembio Diagnostic Systems' antibody test for the novel coronavirus,...
Study finds COVID-19 self-collected swabs on par with physician samples
Specimens that were self-collected by COVID-19 outpatients produced diagnostic outcomes that were nearly identical to those from physician-collected samples...
Cue gets FDA clearance for point-of-care coronavirus test
Cue Health has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for its rapid, portable, point-of-care test for the...

Copyright © 2020 LabPulse.com

Last Updated ls 6/18/2020 9:06:40 AM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current